{"filings":[{"id":2550197,"accession_number":"0001493152-26-040653","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-08-28T21:15:19+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Glucotrack completes 1-for-15 reverse stock split; shares drop to ~798,144","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective Aug 28, 2026 at 4:30 PM ET; every 15 shares became 1 share.","Outstanding shares reduced from 11,972,157 to ~798,144; authorized shares unchanged at 250M.","Split-adjusted trading begins Aug 31, 2026; ticker stays GCTK; new CUSIP 45824Q887.","Approved by stockholders at Aug 18, 2026 annual meeting; fractional shares round up.","Outstanding stock options/warrants adjusted proportionally with corresponding exercise price changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2548676,"accession_number":"0001493152-26-040600","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K/A","filed_at":"2026-08-28T20:28:40+00:00","items":["9.01","2.01"],"status":"ready","headline":"Glucotrack's Lokahi acquisition target: $53K cash, $8.1M H1 loss, going concern doubt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Lokahi had $53,186 cash and no revenue as of June 30, 2026; total assets $2.5M vs liabilities $9.2M.","H1 2026 net loss of $8.1M; R&D expense $1.86M, G&A $4.1M, interest expense $2.16M.","Accumulated deficit $8.8M; shareholders' equity deficit $6.7M as of June 30, 2026.","Independent auditor raised substantial doubt about Lokahi's ability to continue as a going concern.","Cash used in operations $3.6M for six months ended June 30, 2026; no committed financing source."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2503317,"accession_number":"0001493152-26-040332","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-08-27T12:44:31+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack announces 1-for-15 reverse stock split effective Aug 31, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-15 reverse split effective at market open Aug 31, 2026; shares cut from 11,972,157 to ~798,144.","Split aims to regain Nasdaq $1.00 minimum bid compliance; must hold closing bid ≥$1.00 through Nov 9, 2026.","Stockholders approved split at Aug 18, 2026 annual meeting; no fractional shares, rounding up to whole share.","New CUSIP 45824Q887; symbol GCTK unchanged on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2337956,"accession_number":"0001493152-26-039143","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-08-19T13:00:33+00:00","items":["5.07"],"status":"ready","headline":"Glucotrack shareholders approve 1:30 reverse split and warrant inducement at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected; votes for ranged 934,050-961,363; ~1.67M broker non-votes.","Say-on-pay approved: 962,623 for, 122,785 against, 33,960 abstain.","Ratification of CBIZ CPAs P.C. as auditor: 2,621,952 for, 134,874 against.","Reverse stock split up to 1:30 approved: 2,099,338 for, 674,484 against.","Warrant inducement approved: 895,306 for, 138,265 against, 85,797 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2162206,"accession_number":"0001493152-26-036858","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-08-10T20:05:28+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Glucotrack amends White Lion ELOC: issues 2.5M commitment shares, adds true-up provision","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment dated Aug 7, 2026 to July 14, 2026 ELOC with White Lion Capital, LLC.","Company to issue 2,505,513 commitment shares within 1 business day after registration statement effectiveness.","New true-up clause: if Commitment Fee Price < Minimum Price, Company owes up to $1,000,000 minus effective amount within 120 days after Measurement Date.","Issuance exempt under Section 4(a)(2) and Rule 506(b); shares fully earned on effective date.","All other terms of the ELOC Purchase Agreement remain in full force and effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2081356,"accession_number":"0001493152-26-036218","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-08-05T21:20:30+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Glucotrack raises $5.5M in combined equity and convertible debt financing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$2.0M equity PIPE at $0.75/unit: each unit includes one share (or pre-funded warrant) and a 5-year warrant at $1.50.","$3.5M follow-on bridge convertible debt with 8% interest, 9-month maturity, and 22% original issue discount.","Conversion and warrant exercise require stockholder approval; conversion price is lower of Nasdaq minimum or 80% of VWAP.","Proceeds to strengthen balance sheet and provide growth capital for portfolio execution.","E.F. Hutton & Co. served as exclusive advisor to Lōkahi Therapeutics, a Glucotrack subsidiary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1970476,"accession_number":"0001493152-26-035503","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-07-30T21:29:16+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack subsidiary Lokahi advances LT-100 to single-injection strategy after FDA meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lokahi Therapeutics (GCTK subsidiary) plans to simplify LT-100 from 15 intradermal injections to a single subcutaneous injection per visit.","Type C meeting with FDA in May 2026 supported the proposed clinical strategy for LT-100.","Nonclinical minipig study showed subcutaneous administration achieved systemic exposure consistent with prior intradermal data.","Clinical evaluation of single-injection approach expected to begin as early as Q4 2026, with initial readout in H1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1942998,"accession_number":"0001493152-26-035242","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K/A","filed_at":"2026-07-29T21:15:26+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Glucotrack enters exchange agreement to convert $900K promissory note into common stock","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Partitioned $900K note from existing $3.6M promissory note; balance of original note reduced accordingly.","Exchange shares to be issued at Minimum Price (lower of July 24 closing or 5-day average); delivery by Aug 31, 2026.","Exchange under Section 3(a)(9) of Securities Act; no additional cash consideration or commissions paid.","Beneficial ownership limitation of 9.99% applies; shares may be issued in tranches if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1886920,"accession_number":"0001493152-26-034815","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-07-27T20:30:22+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Glucotrack enters exchange agreement to convert $900K note into common stock","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On July 22, 2026, Glucotrack partitioned a $900,000 promissory note from an existing $3.6M note (reduced by prior exchanges).","Investor may exchange portions of the Partitioned Note for common stock at the lower of closing price or 5-day average.","No cash consideration; exchange shares issued under Section 3(a)(9) exemption; beneficial ownership limited to 9.99%.","Original Note remains in effect with reduced balance; Partitioned Note extinguished upon full exchange."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1666877,"accession_number":"0001493152-26-033393","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-07-15T21:20:18+00:00","items":["1.01","2.01","2.03","3.02","5.01","5.02","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Glucotrack completes reverse merger with Lokahi; existing holders get 10% floor","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Lokahi shareholders receive 90% of fully diluted equity; existing Glucotrack holders get at least 10%.","CEO Paul Goode resigns; Erik Emerson appointed CEO and board member effective July 14, 2026.","Bridge financing of $4.45M via senior secured convertible notes and warrants closed same day.","Subsidiary contribution of $7M to Operating Sub for diabetes business, released in installments.","Post-closing: proxy statement for stockholder approval and Nasdaq listing of conversion shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":472076,"accession_number":"0001493152-26-023889","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-05-15T20:45:37+00:00","items":["3.01","9.01"],"status":"ready","headline":"Glucotrack receives second Nasdaq delisting notice; plans to appeal by May 18","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First notice on May 11: non-compliance with minimum bid price of $1.00.","Second notice on May 15: stockholders' equity below $2.5M; additional delisting basis.","Company intends to request hearing by May 18 to appeal both deficiencies.","No assurance of success; stock (GCTK) faces potential delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":445196,"accession_number":"0001493152-26-023202","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-05-14T21:27:11+00:00","items":["2.02","9.01"],"status":"ready","headline":"Glucotrack Q1 net loss $4.3M, IDE submitted to FDA for implantable CGM","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.3M vs $6.8M YoY; cash $3.9M as of March 31, 2026.","Submitted Investigational Device Exemption (IDE) to FDA for fully implantable CBGM; targeting U.S. clinical trial launch in 2H 2026.","Reduced promissory note from $3.6M to ~$1.6M via stock exchange; drew $1.0M under equity line post-quarter.","R&D expenses $2.1M, G&A $2.1M; cash runway expected into early 3Q 2026.","Peer-reviewed data in IEEE Sensors and J. Diabetes Research show sensor stability and 6.8% MARD over 240 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93279,"accession_number":"0001493152-26-021706","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack submits IDE to FDA for US clinical study of implantable CBGM","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Glucotrack submitted an IDE application to the FDA to initiate a US clinical study of its fully implantable continuous blood glucose monitoring (CBGM) system.","CBGM is designed for 3-year sensor longevity, blood-based accuracy, and no on-body wearable component.","Company plans to proceed with US clinical study following FDA review and approval of the IDE.","IDE submission follows years of preclinical evaluation and iterative engineering; data support advancing to clinical evaluation.","CEO Paul Goode stated the submission reflects progress toward offering a discreet, accurate CGM option for diabetes patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93278,"accession_number":"0001493152-26-020747","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Glucotrack converts $988k note into 1.3M shares, reduces debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged a $988k partitioned promissory note for 1,300,000 common shares with an existing investor.","No cash or other consideration paid by the investor; debt reduction with no immediate cash outlay.","Beneficial ownership limitation at 19.9% may cause the exchange to occur in tranches.","Shares issued under Section 3(a)(9) exemption as exchange for outstanding securities.","Company also released an updated investor presentation furnished as Exhibit 99.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93277,"accession_number":"0001493152-26-019788","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack publishes peer-reviewed study showing CBGM accuracy MARD 6.8% over 240 days in ovine model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study in Journal of Diabetes Research shows weighted average MARD of 6.8% across 79 IV glucose tolerance tests in ovine model.","34 devices implanted in 17 sheep; no device-related adverse events observed over up to 240 days.","Results support path to IDE submission with FDA for further clinical development toward commercialization.","Prior first-in-human study demonstrated MARD of 7.7% with 99% data capture and no serious adverse events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93276,"accession_number":"0001493152-26-016507","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Glucotrack exchanges $600K promissory note for 895,000 common shares in debt-to-equity swap","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partitioned $600K from $3.6M original note and exchanged it for 895K shares of common stock.","Exchange done under Section 3(a)(9) exemption; no cash or other consideration paid by investor.","Issuance subject to 19.9% beneficial ownership limitation; shares may be issued in tranches.","Original note reduced by $600K, otherwise remains in full force.","Holding period of original note (Sept 2025) tacks to exchange shares for Rule 144 purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104764,"accession_number":"0001493152-26-013654","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Glucotrack reports FY2025 net loss $19.4M; cash $7.4M; plans IDE filing Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2025 was $19.4M, down from $22.6M in 2024; no product revenue.","Cash and equivalents $7.4M at Dec 31, 2025, up from $5.6M; raised $4.0M private placement in Dec 2025.","R&D expenses $9.8M vs $9.5M; G&A $6.3M vs $5.1M year-over-year.","Expects to file IDE with FDA in Q2 2026 to start US clinical feasibility study of implantable CBGM in H2 2026.","Believes existing cash sufficient only through Spring 2026 to fund IDE submission and trial initiation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104763,"accession_number":"0001493152-26-013095","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack to file IDE with FDA for implantable CBGM in Q2 2026, citing positive trial results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Brazil first-in-human study (Dec 2024-Jan 2025) showed MARD 7.7%, 99% data capture, and zero serious adverse events.","Australia feasibility study started July 2025; findings are incorporated for planned US trial.","Three US patents issued Oct/Nov 2025 covering sensor chemistry, intravascular lead, and low-power electronics.","Expects to file IDE with FDA in Q2 2026 and initiate US clinical study in H2 2026, pending approval.","Reinforced commercial foundation: market research, reimbursement pathway, dual-source manufacturing, seasoned leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104762,"accession_number":"0001493152-26-010049","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Glucotrack shareholders approve stock issuances for ELOC and warrants; ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Votes: ELOC proposal: 126,610 for, 18,261 against, 7,846 abstain, 293,631 non-votes.","Warrant issuance proposal: 26,134 for, 18,151 against, 7,841 abstain, 293,631 non-votes, 100,591 excluded shares.","Auditor ratification passed overwhelmingly: 431,871 for, 4,108 against, 10,369 abstain.","Quorum was 44.1% (446,348 of 1,011,279 shares outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.15,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104761,"accession_number":"0001493152-26-004158","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack receives USPTO approval for three CBGM patents","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three US patents issued by USPTO: US 12,453,494 (Oct 28, 2025), US 12,458,257 and US 12,458,258 (Nov 4, 2025).","Patents protect proprietary sensor chemistry, intravascular lead design, and low-power electronics for the CBGM platform.","The patents strengthen Glucotrack's competitive position and IP protection as it advances its implantable CBGM toward commercialization.","Glucotrack's CBGM is a long-term implantable device with up to 3-year sensor longevity, no wearable component, and direct blood glucose measurement.","The system measures glucose from blood, aiming to provide real-time readings with less lag than interstitial fluid sensors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121042,"accession_number":"0001493152-25-029791","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Glucotrack raises $4.0M via private placement of pre-funded and common warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4.0M from sale of 1,033,591 pre-funded warrants and 2,067,182 common warrants at $3.87/unit.","Common warrants exercise price $3.87, not exercisable until stockholder approval, expire 5 years after approval.","Net proceeds for working capital and general corporate purposes.","Officers and directors entered 90-day lock-up agreements restricting share transfers.","Curvature Securities acted as sole placement agent; receives 7% cash fee and warrants for 124,030 shares at $4.257."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121041,"accession_number":"0001493152-25-029216","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack issues investor presentation; no material details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Issued an investor presentation on December 29, 2025.","Filing text contains no financial or operational specifics.","Presentation content was not included in the 8-K exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121040,"accession_number":"0001493152-25-022305","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Glucotrack reports Q3 net loss of $4.2M; cash $7.9M to fund through Q1 2026; IDE submission Spring 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 net loss $4.2M ($4.64 per share) vs $5.1M in Q3 2024; nine-month net loss $15.8M.","Cash and equivalents $7.9M at Sep 30, 2025; expected to fund operations through first quarter 2026.","Secured $3M convertible note ($3.6M principal) and $20M ELOC; proceeds to repay note and eliminate warrant dilution.","IDE submission for CBGM to FDA expected Spring 2026; long-term feasibility study initiated in Australia."],"consensus_eps_estimate":null,"consensus_eps_actual":30.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121039,"accession_number":"0001493152-25-021320","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":[],"status":"ready","headline":"Glucotrack special meeting adjourned and cancelled due to lack of quorum","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Only 17.6% of 158,370 outstanding shares were represented at reconvened meeting on Nov 7, 2025.","Meeting was permanently adjourned and cancelled because quorum was not achieved.","This follows an earlier adjournment on Oct 31, 2025 for the same reason.","No proposals were voted on; no business was conducted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121038,"accession_number":"0001493152-25-020992","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":[],"status":"ready","headline":"Glucotrack special meeting adjourned due to lack of quorum; reconvenes Nov 7","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Only 16.4% of outstanding shares (899,410 total) were represented, failing to constitute a quorum.","Adjournment proposal approved: 136,928 votes for, 8,655 against, 1,923 abstain.","Meeting adjourned to November 7, 2025 at 12:00 p.m. ET to solicit additional proxies for the Issuance Proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121037,"accession_number":"0001493152-25-020607","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack reconvenes special meeting Nov 7 for vote on $20M equity purchase with Sixth Borough Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting reconvenes November 7, 2025 at 12 p.m. ET to vote on Equity Purchase Agreement with Sixth Borough Capital Fund LP.","Agreement allows issuance of more than 20% of outstanding common stock for up to $20 million under NASDAQ Rule 5635(d).","Record date for voting is September 23, 2025; Board unanimously recommends voting FOR all proposals.","Shareholders can vote by telephone, online, or by returning proxy card; assistance available via Sodali & Co."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121036,"accession_number":"0001493152-25-020072","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack adds Dr. Usman Latif to clinical advisory team for integrated glucose monitoring","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appoints Usman Latif, MD, MBA, a neuromodulation and PDN expert, to its clinical advisory team.","Dr. Latif is Associate Professor at Kansas University Medical Center and board-certified anesthesiologist.","Company aims to integrate glucose sensing into spinal cord stimulator leads for PDN patients.","PDN affects ~1 in 5 Americans with diabetes, over 7 million people.","Long-term preclinical study completed showing feasibility and safety of epidural glucose monitoring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121035,"accession_number":"0001493152-25-019834","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack reminds shareholders to vote on Oct 31 special meeting for equity purchase with Sixth Borough Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting on October 31, 2025 at 12 p.m. ET; record date is September 23, 2025.","Proposal concerns an Equity Purchase Agreement with Sixth Borough Capital Fund.","Board unanimously recommends voting 'FOR' all proposals; proxy statement filed Oct 3.","Shareholders encouraged to vote by telephone, online, or proxy; help via Sodali & Co."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137670,"accession_number":"0001493152-25-013290","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Glucotrack issues $3.6M convertible note at $3M price; ELOC proceeds to repay","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $3.6M convertible promissory note for $3M purchase price ($600K OID), no interest, due in 12 months or upon Qualified Financing.","Conversion price floor of $4.87/share; converts into equity of next financing raising ≥$5M.","Simultaneously entered $20M ELOC with Sixth Borough Capital; 100% of ELOC net proceeds repay note pre-stockholder approval, 50% post.","Note is unsecured, no restrictive covenants; standard events of default include bankruptcy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137669,"accession_number":"0001493152-25-013094","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Glucotrack signs up to $20M equity purchase agreement with Sixth Borough Capital Fund","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Investor committed to buy up to $20M of common stock over 24 months at company's discretion.","Regular purchase price at 97% of VWAP; add-on/intraday at 95% of VWAP.","Commitment fee of 1.5% ($300k) payable in cash, stock, or warrants on Commencement Date.","Exchange cap of 179,792 shares (19.99% of outstanding) unless stockholder approval or price condition met.","Investor prohibited from short sales; company may terminate pact with 1 business day notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137668,"accession_number":"0001493152-25-011975","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glucotrack H1 net loss $11.6M; cash $9.6M; on track to implant first CBGM patients in Australia Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.6M for H1 2025 vs $7.4M prior year; operating expenses rose $0.9M.","Cash and equivalents $9.6M as of June 30, 2025, expected to fund operations through 2025.","Received ethical approval in Australia; first patient implants in multicenter feasibility study expected Q3 2025.","Repurchased Series A warrants, eliminating warrant liability accounting and dilution overhang.","Positive first-in-human CBGM data reported: MARD 7.7%, 99% data capture, no serious adverse events."],"consensus_eps_estimate":null,"consensus_eps_actual":34.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137667,"accession_number":"0001493152-25-011630","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack appoints David S. Hirsh, MD as Medical Director, Cardiology","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Hirsh, a cardiac electrophysiologist, joins Glucotrack's clinical advisory team for its CBGM program.","He will oversee clinical and educational initiatives supporting the CBGM's intravascular placement approach.","Glucotrack is advancing its CBGM through a long-term OUS early feasibility study and upcoming US pilot study.","CBGM is a long-term implantable system measuring glucose directly from blood, with up to 3-year sensor life."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137666,"accession_number":"0001493152-25-011509","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack to exhibit CBGM at ADCES; touts progress toward US pilot study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Presenting at ADCES Annual Meeting Aug 8-11, 2025 in Phoenix, AZ; CBGM at Booth #1724.","Poster: 'Endocrinologists’ Perspectives on an Implantable CBGM' on Aug 9, 12:00-1:00 PM MST.","Preparing to begin long-term early feasibility study after successful initial clinical validation.","CBGM is fully implantable, lasts up to 3 years, measures blood glucose directly with no on-body wearable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137663,"accession_number":"0001493152-25-011423","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K/A","filed_at":"2025-07-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Glucotrack dismisses Grant Thornton Israel as auditor, engages CBIZ CPAs effective July 18, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissal effective July 18, 2025; Grant Thornton reports for past two years included going-concern explanatory paragraph but no adverse opinion.","No disagreements on accounting principles or practices; material weaknesses in internal controls previously disclosed.","Audit committee engaged CBIZ as successor independent registered public accounting firm for FY 2025.","Grant Thornton provided letter dated July 25, 2025, filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137665,"accession_number":"0001493152-25-011386","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Glucotrack dismisses Grant Thornton, engages CBIZ as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee approved dismissal of Fahn Kanne & Co. Grant Thornton Israel and engagement of CBIZ CPAs P.C., effective July 18, 2025.","Grant Thornton's reports for FY2024 and FY2023 included a going-concern explanatory paragraph but were otherwise unqualified.","No disagreements with Grant Thornton on accounting principles or audit scope during FY2024, FY2023, or subsequent interim period.","Material weaknesses in internal control over financial reporting previously disclosed (IT controls, accounting personnel, segregation of duties) were discussed with Grant Thornton.","Company will file Grant Thornton's response letter by amendment within two business days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137664,"accession_number":"0001641172-25-018104","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack repurchases ~49,700 Series A warrants, cuts potential dilution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repurchased over 90% of Series A Warrants on June 30, 2025 for cash on hand in a negotiated transaction.","Approximately 4,300 Series A Warrants remain outstanding; company expects to buy back most of those.","Series B Warrants had been previously extinguished in exchange for common stock as of March 31, 2025.","Buyback eliminates warrant liability accounting and reduces future share dilution overhang."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155043,"accession_number":"0001641172-25-016387","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack reports positive final first-in-human CBGM study results with MARD 7.7%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study met all endpoints; MARD 7.7% across 122 matched pairs, 99% data capture, no serious adverse events.","92% of readings in green zone of Diabetes Technology Society Error Grid, none in unsafe zones.","Ten participants with Type 1 or Type 2 diabetes; device implanted via subclavian vein, monitored 4 days.","Glucotrack expects to initiate long-term early feasibility study in Q3 2025.","OneTwo Analytics applied AI/ML analytics to validate performance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155042,"accession_number":"0001641172-25-015194","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Glucotrack executes 1-for-60 reverse stock split effective June 13, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split approved by stockholders on May 22; reduces outstanding shares from 34,047,337 to ~567,456.","No fractional shares issued; rounding up to next whole share for odd lots.","Ticker remains GCTK; split-adjusted trading begins June 16, 2025; new CUSIP 45824Q804.","Historical per-share net loss recast: FY2024 post-split basic loss $4,101.94 vs pre-split $68.44.","Q1 2025 post-split basic loss $40.14 vs pre-split $0.67; share count adjusted accordingly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155041,"accession_number":"0001641172-25-014803","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack announces 1-for-60 reverse stock split effective June 16, 2025 to meet Nasdaq bid price rule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-60 reverse stock split approved by shareholders on May 22, 2025, effective at market open on June 16, 2025.","Outstanding shares reduced from ~32.5M to ~542,356; no fractional shares issued, rounding up to next whole share.","Reverse split intended to bring GCTK into compliance with Nasdaq $1.00 minimum bid price requirement.","Company warns it may be delisted if it becomes deficient on any Nasdaq rule before September 29, 2025.","CUSIP changes to 45824Q804; trading symbol remains GCTK."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155040,"accession_number":"0001641172-25-013543","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack to present first-in-human CBGM data at ADA 85th Scientific Sessions","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Will present safety & performance data from first-in-human trial of implantable continuous blood glucose monitor (CBGM).","Live presentation by CSO Mark Tapsak on June 21 in Innovation Hub; poster session June 22.","CBGM measures glucose directly from blood, lasts up to 3 years, no on-body wearable.","Company preparing for next clinical phase (long-term feasibility study)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155039,"accession_number":"0001641172-25-012287","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Glucotrack shareholders approve reverse stock split (up to 1:100) and increase equity plan shares to 7.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected with ~59% of votes cast in favor; broker non-votes amounted to ~5.45M on each nominee.","Reverse stock split authorized at a ratio not exceeding 1:100; management will determine exact ratio.","Equity incentive plan share pool increased to 7.5 million shares from prior limit.","Auditor Fahn Kanne & Co. Grant Thornton Israel ratified with ~91% of votes cast in favor.","Quorum of 44.32% achieved with 11,339,896 shares represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155038,"accession_number":"0001641172-25-011610","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack forms Patient Advisory Board to guide implantable CBGM development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patient Advisory Board (PAB) formed with leading diabetes patient advocates and voices.","Inaugural PAB meeting held on May 3, 2025; will convene regularly.","PAB aims to keep patient insights at the forefront of long-term implantable CBGM development.","CBGM is designed for up to 3 years of continuous blood glucose monitoring, no wearable component.","CBGM is an Investigational Device limited by federal law to investigational use."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155037,"accession_number":"0001641172-25-010377","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glucotrack Q1 net loss widens to $6.8M; cash $9.1M; on track for CBGM study Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.8M vs $2.9M YoY; includes $3.4M non-cash derivative liability change.","R&D expense $1.9M (down $0.2M); MG&A $1.6M (up $0.8M on legal/professional fees).","Cash $9.1M at Mar 31, 2025 vs $5.6M at Dec 31, 2024; $6.4M from financing.","First patients in Australian CBGM feasibility study expected Q3 2025; FDA IDE pilot study expected Q4 2025.","First-in-human study met primary endpoint; no device-related serious adverse events."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155036,"accession_number":"0001641172-25-009849","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack receives ethics approval for 1-year CBGM clinical study in diabetes patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ethical approval from St. Vincent's Hospital Melbourne HREC for long-term CBGM study in type 1/2 diabetes.","Study plans up to 30 participants; initial 1-year evaluation, possible extension to 3 years.","First patient implants expected by July 2025; Principal Investigators Prof. David O'Neal and Assoc. Prof. Neale Cohen.","CBGM is implantable, measures blood glucose directly (vs interstitial fluid), no wearable component."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155035,"accession_number":"0001641172-25-006651","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack issued investor presentation on April 29, 2025; no details provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation furnished as Exhibit 99.1; content not disclosed in filing.","No financial figures, forecasts, or material updates included.","Filing under Regulation FD; information not deemed filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155034,"accession_number":"0001641172-25-004977","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack joins EU-funded FORGETDIABETES bionic pancreas initiative","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Glucotrack's CBGM will provide real-time glucose data for automated insulin delivery system.","FORGETDIABETES is funded by EU Horizon 2020 (€75B program) to develop a long-term bionic pancreas.","Partnership with University of Padova and other European research institutions.","Glucotrack CBGM is long-term implantable (3-year sensor), no on-body wearable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155033,"accession_number":"0001641172-25-002802","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Glucotrack receives Nasdaq delisting notice for bid price non-compliance; plans to appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Glucotrack on April 2, 2025 of delisting due to bid price below $1.00 for 30 consecutive business days.","Company intends to request a hearing by April 9, 2025, which will stay the suspension pending Panel decision.","Compliance with Bid Price Rule was previously regained in November 2024; now again non-compliant.","No immediate impact on trading under symbol GCTK; outcome of appeal uncertain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155032,"accession_number":"0001641172-25-002525","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack partners with OneTwo Analytics for AI-driven clinical data analysis of implantable CBGM","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Glucotrack (GCTK) enters collaboration with OneTwo Analytics AB to apply AI/ML analytics on its CBGM clinical study data.","CBGM is a long-term implantable device that measures glucose directly from blood, no external component, 3-year sensor life.","OneTwo Analytics specializes in diabetes data analytics; collaboration aims to quantify long-term benefits of CBGM.","No financial terms disclosed; agreement focuses on data analysis for clinical evaluation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173562,"accession_number":"0001641172-25-001831","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glucotrack FY2024 net loss $22.6M; completes first human CBGM study, expects IDE in Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.6M vs $7.1M in 2023; R&D expense $9.5M (+$4.8M YoY) on increased product development activities.","Cash $5.6M at Dec 31, 2024; pro forma $11.9M after Q1 2025 offerings; raised $16.3M since Nov 2024.","First human clinical study of CBGM met primary endpoint with no device-related serious adverse events.","Appointed new CFO, VP Regulatory, VP Clinical Ops; expanded Medical Advisory Board.","Anticipates IDE approval from FDA in Q4 2025; long-term study in Australia expected Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173561,"accession_number":"0001493152-25-010873","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack to present first-in-human CBGM trial data at ATTD 2025 conference in Amsterdam","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Safety and performance data from first-in-human trial of implantable CBGM system to be presented at ATTD conference, March 19-22, 2025.","Device measures glucose directly from blood, not interstitial fluid, with no on-body wearables, designed for 3-year continuous monitoring.","Trial is an early feasibility study in adults with diabetes; results support advancement to chronic implant study.","CEO Paul Goode highlights potentially transformative advancement in diabetes management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2025-03-19T23:59:59+00:00|173561"}